IVIG is an antibody-based product that contains the spectrum of
antibodies normally present in healthy adult human plasma. It can
be used to provide ongoing treatment for primary and secondary immune
deficiencies as well as replacement therapy as in Idiopathic Thrombocytopenic
Purpura (ITP) by providing a broad selection of antibodies that
mimic a healthy immune system.
VIG is an antibody-based product that is designed to treat smallpox
vaccine-related complications. These complications range from localized
adverse reactions to inflammation of the brain. VIG is stockpiled
by governmental organizations as an adjunct to smallpox vaccine
for two reasons: first, to treat complications in the case that
a government mass vaccinates its citizens with smallpox vaccine;
second, to be given to immuno-suppressed patients who cannot receive
the vaccine in the event of a smallpox terrorist attack.
HBIG is an antibody-based product that contains antibodies specific
to hepatitis B, or HBV. HBV can cause lifelong infection, scarring
of the liver, liver cancer, liver failure and death. Many patients
with chronic HBV infection require a liver transplant. After liver
transplant surgery, there is a high risk that these transplant patients
will be reinfected with HBV, which destroys the transplanted liver.
To prevent reinfection, these patients require life long treatment
for HBV. HBIG is one of the treatments used to prevent reinfection
of the transplanted liver.